Um neutracêutico para melhorar a eficácia de vacinas em países em desenvolvimento
- Food
- Corporate social responsibility
- Health care
- Economic development
- Sustainable development
- Microfinance
- Social enterprise
Exemplo: Compartilhe um exemplo específico de como essa solução faz a diferença, inclua situações práticas.
Mercado ou Setor: Quais projetos ou organizações estão solucionando o mesmo problema que você e como essas propostas diferem da sua?
História de fundação
Nicolas
I am an expert scientist in molecular biology at GSK Vaccines (Belgium). I hold a PhD in Immunology from the Université de la Méditerranée (France) and completed post-doctoral training in Cancer Immunogenetics at the Gustave Roussy Institute (France). I have always wanted to participate in the quest towards new classes of well tolerated anti-cancer therapies and thus decided to join the GSK Antigen-Specific Cancer Immunotherapeutic (ASCI) program three years ago. My group participates in the characterization of tumor-specific antigens and related biomarkers at the molecular level and their implementation in clinical trials.
In my opinion, there are two kinds of people: people who have ideas but never do anything about them, and people who do something about their ideas. I have always wanted to be one of the doers. I like to generate new ideas which address issues and tackle the underlying causes of problems to create strategies and a vision for the future. In other words, I have creative and innovative thinking skills. Moreover, I am determined, persevering, diplomatic and able to lead cross-functional teams.
, WBR, Rixensart
, KAD, Ouagadougou
All developping countries
Assistência Médica
As informações que você fornecer aqui serão usadas para preencher todas as partes do seu perfil deixadas em branco, como interesses, informação da organização e website. Nenhuma informação do contato será tornada pública. Por favor, desmarque aqui se você não deseja que isso aconteça..
Ideia (você está para lançar)
GSK corporate social responsibility (CSR) represents a standard in the pharmaceutical industry field, notably based on its social initiatives in least developed countries (LDCs). The development of a nutraceutical produced by the LDCs themselves to improve vaccine efficacy in LDCs would constitute a new social business solution fully aligned with GSK CSR and would benefit from the scientific expertise and the know-how of GSK Vaccines and GSK Consumer Healthcare.
The solution that I propose has not been launched yet. I was waiting for the opportunity to make my idea a reality. That’s the reason why I jumped at the chance when I heard about the League of the Intrapreneurs Competition. I am convinced that this initiative can achieve success with the support of GSK.
The projected worldwide impact of the proposed solution over the next 1-3 years can be summarized in two points:
-An improvement of health in LDCs through a better nutrition and vaccination effectiveness.
-An improvement of the living conditions of rural communities by creating jobs through involvement in all stages of the business model: supply, production, sales and through sustainable local microeconomics based on fair trading of raw materials, good working conditions, and fair wage and employee empowerment.
Among GSK vaccine portfolio, we can distinguish a rotavirus vaccine, a pneumococcal vaccine and potentially a malaria vaccine in the near future, which represent weapons against the three leading causes of childhood mortality in developing countries. The development of a tailor-made nutraceutical for vaccine effectiveness improvement in LDCs will support via a complementary, sustainable and profitable way one of the GSK responsible business goals: “health for all.”
As a science-led global healthcare company, GSK is committed to developing practical ideas that have a significant social impact, especially in the least developed countries, a policy that reflects its recognised corporate social responsibility. That is the reason why this initiative will benefit from the support and the expertise of GSK Consumer Healthcare and GSK Vaccines in terms of scientific innovation, manufacturing and commercial strategies. Internal resources and funds to be allocated to this project will be defined in due time depending on the issue of this competition.
As a social business enterprise addressing a social objective, the financial strategy will consist in generating a symbolic dividend of 1 to 5% annually that will be re-invested to expand the company (building of new factories) and improve the product(s). It should be noticed that this financial model will be put in place once the founder(s) who have contributed to the seed capital will have recovered their investment. At the same time various funders such as governments, private and public non-profit foundations, corporations and impact investors will be approached and asked to participate in the capital increase over time.
An internal partnership will be established between GSK Consumer Healthcare and GSK Vaccines for the development of the nutraceutical prototype and the proof-of-concept in terms of vaccine efficacy improvement. A potential external partnership with the Grameen Bank or a similar organization could be considered to support the microfinance programs that will be offered to the farmers.
I have received valuable support from my supervisors and have established key contacts with GSK Consumer Healthcare to move forward with this initiative. I have not received any push-back so far.